BioAtla to Present Clinical Data for Mecbotamab Vedotin (BA3011) in Soft Tissue Sarcoma at SITC 2025
BioAtla (NASDAQ: BCAB) announced clinical data for its AXL-targeting ADC mecbotamab vedotin (BA3011) will be presented at the Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting, Nov 5-9, 2025, at National Harbor, MD.
The presentation by Dr. Mihaela Druta on Nov 7, 2025 reports a median overall survival (OS) of 21.5 months among 44 patients with treatment-refractory leiomyosarcoma, liposarcoma, and undifferentiated pleomorphic sarcoma (abstract #523). Poster session timing to be announced; slides will be posted in the company Publication section after the presentation.
BioAtla (NASDAQ: BCAB) ha annunciato dati clinici per il suo ADC mirato a AXL mecbotamab vedotin (BA3011) che saranno presentati al SITC 2025 Annual Meeting, dal 5 al 9 novembre 2025, a National Harbor, MD.
La presentazione della Dott.ssa Mihaela Druta il 7 novembre 2025 riporta una sorveglianza globale mediana (OS) di 21,5 mesi tra 44 pazienti con leioniomosarcoma refrattario al trattamento, liposarcoma e sarcoma pleomorfo indifferenziato (abstract #523). L'orario della sessione poster sarà annunciato; le diapositive saranno pubblicate nella sezione Publication dell'azienda dopo la presentazione.
BioAtla (NASDAQ: BCAB) anunció datos clínicos para su ADC dirigido a AXL mecbotamab vedotin (BA3011) que se presentarán en la Reunión Anual 2025 de la Society for Immunotherapy of Cancer (SITC), del 5 al 9 de noviembre de 2025, en National Harbor, MD.
La presentación de la Dra. Mihaela Druta el 7 de noviembre de 2025 informa una mediana de supervivencia global (OS) de 21,5 meses entre 44 pacientes con leiomiosarcoma refractario al tratamiento, liposarcoma y sarcoma pleomórfico indiferenciado (resumen #523). Se anunciará la hora de la sesión de póster; las diapositivas se publicarán en la sección Publication de la empresa después de la presentación.
BioAtla (NASDAQ: BCAB)가 AXL 표적 ADC mecbotamab vedotin (BA3011)에 대한 임상 데이터를 발표하며 SITC 2025 연례 학회에서 발표될 예정이며, 2025년 11월 5-9일, 매리랜드주 내셔널 하버에서 개최됩니다.
Dr. Mihaela Druta의 2025년 11월 7일 발표는 치료에 저항하는 평활근육종, 지방육종, 미분화 다형성 육종(abstract #523) 중 중간 무작위 생존(OS) 21.5개월을 보고합니다. 포스터 세션 시간은 추후 공지되며, 발표 후 회사 Publication 섹션에 슬라이드가 게시됩니다.
BioAtla (NASDAQ: BCAB) a annoncé des données cliniques pour son ADC ciblant l'AXL mecbotamab vedotin (BA3011) qui seront présentées lors de SITC 2025 Annual Meeting, du 5 au 9 novembre 2025, à National Harbor, MD.
La présentation de la Dr. Mihaela Druta le 7 novembre 2025 rapporte une survie globale médiane (OS) de 21,5 mois chez 44 patients atteints de léiomyosarcome réfractaire au traitement, liposarcome et sarcome pleomorphe indifférencié (résumé n°523). L'horaire de la session poster sera annoncé; les diapositives seront publiées dans la section Publication de l'entreprise après la présentation.
BioAtla (NASDAQ: BCAB) gab klinische Daten zu seinem AXL-zielenden ADC mecbotamab vedotin (BA3011) bekannt, die auf der SITC 2025 Annual Meeting vom 5. bis 9. November 2025 in National Harbor, MD, präsentiert werden.
Die Präsentation von Dr. Mihaela Druta am 7. November 2025 berichtet über eine Medianes Gesamtüberleben (OS) von 21,5 Monaten bei 44 Patienten mit behandlungsresistentem Leiomyosarkom, Liposarkom und un Differentiated Pleomorphic Sarcoma (Abstract Nr. 523). Die Poster-Sitzung wird zeitlich bekannt gegeben; Folien werden nach der Präsentation im Publication-Bereich des Unternehmens veröffentlicht.
BioAtla (NASDAQ: BCAB) أعلنت عن بيانات سريرية لـ ADC المستهدف لـ AXL mecbotamab vedotin (BA3011) والتي ستعرض في اجتماع SITC 2025 السنوي، في 5-9 نوفمبر 2025، في National Harbor، MD.
التقديم من قبل الدكتورة ميهايلا دروتا في 7 نوفمبر 2025 يذكر متوسط البقاء على قيد الحياة (OS) 21.5 شهرًا بين 44 مريضًا مصابًا بسرطان لُيُّوميّا ملساء مقاوم للعلاج، ساركوما دهنيّة، وساركوما متعدد الأشكال غير المتمايزة (الملخص رقم 523). سيتم إعلان وقت جلسة الملصقات؛ ستُنشر الشرائح في قسم Publications للشركة بعد العرض.
BioAtla (NASDAQ: BCAB) 宣布关于其靶向 AX L 的抗体药物偶联物 mecbotamab vedotin (BA3011) 的临床数据，将在 SITC 2025 年度会议上公布，会议时间为 2025 年 11 月 5-9 日，地点在 National Harbor, MD。
Mihaela Druta 博士于 2025 年 11 月 7 日 的演讲报告了在 44 例治疗抵抗性肌平滑肌肉瘤、脂肪肉瘤及未分化的多形性肉瘤中，中位总生存(OS) 为 21.5 个月（摘要 #523）。海报会话时间待定；幻灯片将在演讲后在公司 Publication 部分发布。
- None.
- None.
SAN DIEGO, Oct. 03, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics using its proprietary CAB platform for the treatment of solid tumors, today announced that clinical data for its investigational AXL-targeting antibody-drug conjugate (ADC), mecbotamab vedotin (BA3011), will be presented at the upcoming Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting to be held at National Harbor, MD from November 5-9, 2025.
The presentation, titled “Median OS of 21.5 months among 44 patients with treatment-refractory leiomyosarcoma, liposarcoma, and undifferentiated pleomorphic sarcoma treated with mecbotamab vedotin, an AXL-targeting ADC”, will be delivered by Dr. Mihaela Druta of Moffitt Cancer Center on Friday, November 7, 2025. The abstract (#523) will be featured in the poster session, with presentation time to be announced.
A copy of the presentation materials can be accessed on the “Publication” section of the Company’s website at www.bioatla.com once the presentation has concluded.
About BioAtla®, Inc.
BioAtla is a global clinical-stage biotechnology company with operations in San Diego, California, and in Beijing, China through its contractual relationship with BioDuro-Sundia, a provider of preclinical development services. Utilizing its proprietary CAB platform technology, BioAtla develops novel, reversibly active monoclonal and bispecific antibodies and other protein therapeutic product candidates. CAB product candidates are designed to have more selective targeting, greater efficacy with lower toxicity, and more cost-efficient and predictable manufacturing than traditional antibodies. BioAtla has extensive and worldwide patent coverage for its CAB platform technology and products with greater than 780 active patent matters, more than 500 of which are issued patents. Broad patent coverage in all major markets include methods of making, screening and manufacturing CAB product candidates in a wide range of formats and composition of matter coverage for specific products. To learn more about BioAtla, Inc., visit www.bioatla.com.
Internal Contact:
Richard Waldron
Chief Financial Officer
BioAtla, Inc.
rwaldron@bioatla.com
858.356.8945
External Contact:
Joyce Allaire
LifeSci Advisors, LLC
jallaire@lifesciadvisors.com
FAQ
When will BioAtla (BCAB) present mecbotamab vedotin clinical data at SITC 2025?
What efficacy result will BioAtla share for BA3011 (BCAB) at SITC 2025?
Which patient populations were included in the BA3011 (BCAB) SITC 2025 poster abstract #523?
How can investors access BioAtla (BCAB) presentation materials after SITC 2025?
Who is presenting BioAtla's BA3011 data at SITC 2025?
What is the SITC 2025 abstract number for BioAtla's mecbotamab vedotin data?
